Work

Leveraging the baculovirus-insect cell expression system for optimal AAV scale-up

Year: 2024

Type: article

Abstract: David McCall, Senior Editor, BioInsights, speaks to VectorY Therapeutics’ Barbara Sanders, Co-founder and CTO, and Femke Hoeksema, Director of Process Development, about their innovative work on gene therapies for neurodegenerative diseases, including vectorized antibody treatments for amyotrophic lateral sclerosis. They also discuss the considerations and advantages in utilizing a baculovirus-based AAV production system versus other upstream viral vector production platforms.

Source: Cell and Gene Therapy Insights

DOI: 10.18609/cgti.2024.129

Authors: Barbara Sanders, Femke Hoeksema

Institution: Stedelijk Museum Amsterdam

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4417368808

FWCI:

Cites:

Cited by:

Related to: